Published guidance, NICE advice and quality standards | Guidance

Showing 211 to 220 of 797

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence	TA817	10 August 2022	10 August 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer	TA812	3 August 2022	3 August 2022
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	TA813	3 August 2022	3 August 2022
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	TA814	3 August 2022	3 August 2022
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	TA811	27 July 2022	27 July 2022
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	TA809	20 July 2022	20 July 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	TA810	20 July 2022	20 July 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	TA803	13 July 2022	13 July 2022
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	TA805	13 July 2022	13 July 2022
Belimumab for treating lupus nephritis (terminated appraisal)	TA806	13 July 2022	13 July 2022